CureVac Future Growth
Future criteria checks 3/6
CureVac's revenue is forecast to decline at 16.3% per annum while its annual earnings are expected to grow at 19% per year. EPS is expected to grow by 24.5% per annum. Return on equity is forecast to be -16.9% in 3 years.
Key information
19.0%
Earnings growth rate
24.5%
EPS growth rate
| Biotechs earnings growth | 0% |
| Revenue growth rate | -16.3% |
| Future return on equity | -16.9% |
| Analyst coverage | Good |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 106 | -66 | 20 | N/A | 5 |
| 12/31/2025 | 71 | -101 | 60 | N/A | 7 |
| 12/31/2024 | 530 | 180 | 73 | N/A | 5 |
| 6/30/2024 | 66 | -278 | -330 | -290 | N/A |
| 3/31/2024 | 59 | -273 | -312 | -265 | N/A |
| 12/31/2023 | 54 | -260 | -323 | -268 | N/A |
| 9/30/2023 | 43 | -302 | -335 | -273 | N/A |
| 6/30/2023 | 38 | -301 | -325 | -249 | N/A |
| 3/31/2023 | 50 | -291 | -338 | -249 | N/A |
| 12/31/2022 | 67 | -249 | -379 | -286 | N/A |
| 9/30/2022 | 97 | -122 | -527 | -420 | N/A |
| 6/30/2022 | 115 | -219 | -758 | -659 | N/A |
| 3/31/2022 | 117 | -313 | -782 | -673 | N/A |
| 12/31/2021 | 103 | -412 | -861 | -733 | N/A |
| 9/30/2021 | 68 | -468 | -228 | -109 | N/A |
| 6/30/2021 | 44 | -361 | N/A | N/A | N/A |
| 3/31/2021 | 56 | -219 | 250 | 329 | N/A |
| 12/31/2020 | 49 | -129 | 475 | 522 | N/A |
| 9/30/2020 | 50 | -107 | 36 | 62 | N/A |
| 3/31/2020 | 17 | -102 | -82 | -67 | N/A |
| 12/31/2019 | 17 | -100 | -99 | -87 | N/A |
| 12/31/2018 | 13 | -71 | -89 | -74 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CVAC N is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (8.1%).
Earnings vs Market: CVAC N is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CVAC N is expected to become profitable in the next 3 years.
Revenue vs Market: CVAC N's revenue is expected to decline over the next 3 years (-16.3% per year).
High Growth Revenue: CVAC N's revenue is forecast to decline over the next 3 years (-16.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CVAC N is forecast to be unprofitable in 3 years.